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Abstract
Background: In preclinical studies, müllerian inhibiting substance (MIS) has a protective affect against breast
cancer. Our objective was to determine whether serum MIS concentrations were associated with cancerous or
precancerous lesions. Blood from 30 premenopausal women was collected and serum extracted prior to their
undergoing breast biopsy to assess a suspicious lesion found on imaging or physical examination. Based on biopsy
results, the serum specimens were grouped as cancer (invasive or ductal carcinoma in situ), precancer (atypical
hyperplasia or lobular carcinoma in situ), or benign.
Findings: Serum from women with cancer and precancer (p = .0009) had lower MIS levels than serum from
women with benign disease.
Conclusion: Our findings provide preliminary evidence for MIS being associated with current breast cancer risk,
which should be validated in a larger population.
Introduction
Müllerian inhibiting substance (MIS), also known as
anti-müllerian hormone, is produced by the granulosa
cells of growing ovarian follicles. The level of MIS varies
throughout a woman’s lifetime. MIS is detectable from
birth, but increases substantively at puberty. After pub-
erty, MIS slowly decreases until it becomes undetectable
after menopause [1]. MIS levels have recently been
linked to breast cancer risk [2]. MIS, a member of the
transforming growth factor (TGF)-b superfamily, is a
140 kDa dimeric glycoprotein that binds to the MIS
type II receptor in breast tissue [3,4]. MIS inhibits the
growth of cultured breast cancer cells through G1 arrest
and the induction of apoptosis [5,6]. An eight-fold
increase in the ratio of apoptotic cells in murine mam-
mary tissue was observed after MIS injection [6]. Based
on these observations, our hypothesis was that MIS
would decrease breast cancer risk in premenopausal
women, and that MIS serum levels would be different in
women with benign breast disease vs. those with precan-
cer or cancer. The objective of our study was to deter-
mine if MIS predicted the benign or malignant nature
of a breast lesion requiring biopsy.
Material and methods
After Institutional Review Board approval, informed
consent was obtained. Thirty blood samples were pro-
spectively collected in serum separator tubes from pre-
menopausal women 38-50 years of age scheduled to
undergo diagnostic breast biopsy to determine the
benign or malignant nature of a suspicious breast lesion
identified on imaging or physical examination. Pregnant
or lactating women, as well as women receiving che-
motherapy or radiation therapy, were not eligible. The
cohort of randomly collected samples included 14 from
women diagnosed with cancer, 8 with precancer and 8
with benign lesions collected between November 2001
and May 2008. Participant samples were classified as
“cancer” i ft h ed i a g n o s t i cb i o p s yd e m o n s t r a t e dd u c t a l
carcinoma in situ or invasive breast cancer; “precancer”
if the biopsy demonstrated atypical hyperplasia or lobu-
lar carcinoma in situ;o r“benign” if the biopsy was
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snap frozen at -80°C until analysis.
Samples were analyzed as a single batch by a scientist
(WQ) blinded as to sample diagnosis using an MIS
ELISA kit (catalog no. DSL-10-14400) from Diagnostic
Systems Laboratories (Webster, TX), according to the
manufacturer’s instructions. The scientist analyzing the
samples was blinded regarding the participant’sd i a g n o -
sis. The kit has a detection limit of 0.006 ng/mL. An
intra-assay CV was calculated for all samples with all
values that were at least three times the detection limit
of the assay. The mean CV was 4.0% (range 0-16.1%).
Values below the detection limit were assigned a value
of half the detection limit, 0.003 ng/ml. The raw data
were right-skewed and not normally distributed based
on the Shapiro-Wilk test. Therefore, the data were loga-
rithm transformed, checked using the same test, and
found not to be significant. The transformed data were
then analyzed. The distribution of MIS levels in the
three risk groups (benign, precancer, and cancer) were
assessed using analysis of variance (ANOVA). Pairwise
differences between risk groups were analyzed using
Fisher’s LSD (least significant difference). Time from
sample collection to analysis, participant age, age at
menarche, body mass index (BMI), whether the partici-
pant had a first degree relative with breast cancer, cur-
rent or ever use of oral contraceptive pills (OCPs) were
assessed for their potential cofounding effects. All ana-
lyses were conducted using SAS JMP software.
Results
Participant demographics are summarized in Table 1.
Twenty-nine of the 30 women reported having a period
within a year prior to enrollment. The one woman who
did not had undergone uterine ablation and was 45
years old at the time of enrollment, with intact ovaries.
Due to her age, she was classified as premenopausal.
Time from sample collection to analysis, participant age,
age at menarche, those with a first degree relative with
breast cancer, ever or current OCP use and BMI did
not significantly differ based on pathologic diagnosis.
MIS was inversely associated with risk of breast cancer
(p = .04) or precancer (p = .02) compared to women
w h oh a dab e n i g nb i o p s y( T a b l e1F i g u r e1 ) .M o r e o v e r ,
MIS was highly inversely associated with the presence of
any disease (cancer or precancer) vs. benign (p = .0009).
We evaluated if there were outliers that made the com-
parison between disease vs. benign not significant. No
such outliers were identified.
Discussion
Since the primary purpose of MIS in males is the regres-
sion of Mullerian structures through the induction of
apoptosis [7], it follows that apoptosis induced by cells
sensitive to MIS in females may protect against malig-
nant transformation. Breast ductal epithelial cells have
MIS receptors which upon stimulation induce apoptosis
and inhibit growth [5,6]. We observed a negative associa-
tion of MIS concentration with cancerous and precancer-
ous breast lesions in premenopausal women 38-50 years
of age. This age range was chosen because breast precan-
cer and cancer is uncommon in women less than 35
years of age [8], and is consistent with the upper age
bound used in a prior report on MIS
2.
Our observation of lower MIS levels in women with
breast precancer and cancer is consistent with both in
vitro and animal studies, which suggest that MIS has a
cancer preventive effect [3,5,6], but is in contrast to an
epidemiologic study [2] which suggested that increased
MIS levels in healthy women were associated with an
increased risk of breast cancer in the future. In that
report, the journal editors noted that the association of
Table 1 Demographics
1
Benign Precancer Cancer
Mean ± SD
Sample size 8814
Time from sample collection to analysis (years) 3.02 ± 1.04 4.19 ± 2.40 2.24 ± 0.49
Participant age 42.4 ± 3.3 45.5 ± 4.5 43.7 ± 4.4
Age at menarche 13.1 ± 1.2 12.6 ± 1.0 12.6 ± 1.6
BMI 30.7 ± 6.9 30.7 ± 10.0 27.4 ± 9.1
MIS (ng/mL) 1.07 ± 0.90 0.30 ± 0.50 0.58 ± 0.80
ln(MIS (ng/mL) -0.27 ± 0.93 -2.91 ± 2.24 -2.31 ± 2.55
Frequency (%)
1st degree relative with breast cancer 1 (12.5%) 3 (37.5%) 2 (14.3%)
Current OCP use 1 (12.5%) 0 (0%) 2 (14.3%)
History of OCP use 4 (50%) 6 (75%) 12 (85.7%)
1: Results for time to sample collection, participant age, age at menarche, body mass index (BMI), and mullerian inhibiting substance (MIS) are mean +/- standard
deviation. Results for 1
st degree relative with breast cancer, current and history of oral contraceptive pill (OCP) use are frequency (%).
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future risk of developing breast cancer is in contrast to
previous preclinical findings and what is known about
the mechanisms of MIS on breast physiology, which
would predict that high MIS concentrations would be
associated with lower risk. The author of the epidemio-
logic study noted that their cohort of case participants
had a lower frequency of oral contraceptive use com-
pared to controls, which is at odds with most reports
[9]. On the other hand, the OCP use in our precancer
and cancer participants was not lower than controls and
trended higher in the cancer group, which may in part
explain the difference in our results. Additionally, our
observations regarding MIS are for current risk, com-
pared to the future risk that was evaluated in the epide-
miologic study.
There are limitations to the current study. The first is
the limited sample size. A second is that MIS, though
associated with disease, was not 100% accurate in differen-
tiating women with precancer or cancer from those with-
out. As such, it is likely that MIS, if validated as associated
with current disease in the breast, will need to be com-
bined with other biomarkers for optimal disease predic-
tion. We evaluated whether there was an outlier which
might have influenced the association of MIS with disease,
but could find none. Our findings provide preliminary evi-
dence for MIS being associated with current breast cancer
risk, which should be validated in a larger population.
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Figure 1 Natural log (ln) levels of MIS in serum collected from
premenopausal women prior to diagnostic breast biopsy.
Colors designate individuals with the following diagnoses: green-
benign; yellow-precancer; red-cancer. Values below the detection
limit were assigned a value of half the detection limit.
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